View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
October 20, 2021

Amgen concludes acquisition of biotech company Teneobio for $2.5bn

Teneobio’s three affiliates, TeneoTwo, TeneoFour and TeneoTen, were spun off to its present equity holders.

Amgen has concluded the acquisition of all outstanding shares of clinical-stage biotechnology firm Teneobio in a deal worth $2.5bn.

Free Report
img

What’s missing from your IPO industry assessment?

IPO activity all but stopped in 2020, as the investment community grew wary of the effects of COVID-19 on economies. No matter how deserving a business was of flotation, momentum was halted by concerns of when a ‘new normal’ of working patterns and trade would set in. Recently, sentiment has changed. Flotations picked up again during the second half of 2021, and now in 2022 the mood is decidedly optimistic. Business leaders have their eyes on fast rebounding economies, buoyant market indices and the opportunity once again to take their businesses public. As a result, global IPOs are expected to hit back this year. With GlobalData’s new whitepaper, ‘IPOs in Consumer and Retail: 5 must-include elements for your prospectus industry report’, you can explore exactly what is needed in the essential literature. GlobalData’s focus lies in the critical areas to get right:
  • Macroeconomic and demographic environment
  • Consumer context
  • Industry environment
  • Competitive environment
  • Route to market
Interested to learn more about what to include in your IPO Industry Assessment report? Download our free whitepaper.
by GlobalData
Enter your details here to receive your free Report.

According to the previously announced agreement, Amgen paid $900m upfront in cash to Teneobio shareholders, who are also eligible for future milestone payments totalling $1.6bn in cash.

With the takeover, Amgen acquired bispecific and multispecific antibody technologies of Teneobio.

These technologies are complementary to the company’s BiTE platform and current antibody expertise.

This will facilitate expediting new molecule discovery and advancement for the treatment of a broad range of ailments in key treatment areas of Amgen.

In addition, Amgen acquired bispecific T cell engager TNB-585 and various preclinical cancer assets in the pipeline, nearing investigational new drug (IND) application filings.

A Phase I asset, TNB-585 is being analysed to treat metastatic castrate-resistant prostate cancer (mCRPC) and complements the prostate cancer portfolio of Amgen.

The portfolio comprises two therapies, acapatamab (AMG 160) and AMG 509, presently in the Phase I developmental stage.

All three drugs leverage dissimilar strategies for the treatment of prostate cancer, which currently required novel therapy options.

Before concluding the deal, three affiliates of Teneobio were spun off to its current shareholders. They include TeneoTwo, developing a bispecific antibody that acts on CD19 on tumour cells and CD3 on T-cells, TNB-486, TeneoFour and TeneoTen.

TeneoFour has anti-CD38 heavy chain antibodies that hinder the enzyme functions of CD38 while TeneoTen is developing bispecific antibodies that target the hepatitis B surface antigen (HBsAg), as well as CD3.

Amgen Research and Development executive vice-president David Reese said: “Amgen is pioneering the application of T cell engagers and a broad array of bi and multispecific biologics to treat a range of human diseases across our therapeutic areas of focus.

“Teneobio’s expertise and technologies will further expand our repertoire of multispecific architectures and advance our overarching mission to develop transformative innovation to bring to market best-in-class products to serve our patients.”

Related Companies

Free Report
img

What’s missing from your IPO industry assessment?

IPO activity all but stopped in 2020, as the investment community grew wary of the effects of COVID-19 on economies. No matter how deserving a business was of flotation, momentum was halted by concerns of when a ‘new normal’ of working patterns and trade would set in. Recently, sentiment has changed. Flotations picked up again during the second half of 2021, and now in 2022 the mood is decidedly optimistic. Business leaders have their eyes on fast rebounding economies, buoyant market indices and the opportunity once again to take their businesses public. As a result, global IPOs are expected to hit back this year. With GlobalData’s new whitepaper, ‘IPOs in Consumer and Retail: 5 must-include elements for your prospectus industry report’, you can explore exactly what is needed in the essential literature. GlobalData’s focus lies in the critical areas to get right:
  • Macroeconomic and demographic environment
  • Consumer context
  • Industry environment
  • Competitive environment
  • Route to market
Interested to learn more about what to include in your IPO Industry Assessment report? Download our free whitepaper.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology